We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > RSK inhibitor

News List

Roche, PhoenixMD collaborate on diagnostic that may help identify triple-negative breast cancer patients who might benefit from RSK inhibitor PMD-026 firstwordpharma
January 17, 2019
In September, PhoenixMD announced that it raised $2.7 million to advance PMD-026 through investigational new drug (IND)-enabling studies and to develop a companion diagnostic to determine which patients have high levels of activated RSK2.
Roche, PhoenixMD collaborate on diagnostic that may help identify triple-negative breast cancer patients who might benefit from RSK inhibitor PMD-026 firstwordpharma
January 17, 2019
In September, PhoenixMD announced that it raised $2.7 million to advance PMD-026 through investigational new drug (IND)-enabling studies and to develop a companion diagnostic to determine which patients have high levels of activated RSK2.